Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer

被引:0
|
作者
Tomonori Minagawa
Yasushi Murata
Shinichiro Uchikawa
Takeshi Uehara
机构
[1] Azumino Red Cross Hospital,Department of Urology
[2] Azumino Red Cross Hospital,Department of Cardiovascular Medicine
[3] Shinshu University School of Medicine,Department of Laboratory Medicine
来源
International Journal of Clinical Oncology | 2010年 / 15卷
关键词
Prostate cancer; Pericardial metastasis; Prostate-specific antigen;
D O I
暂无
中图分类号
学科分类号
摘要
An 82-year-old man who was receiving treatment for prostate cancer and cholangiocellular carcinoma was admitted to our hospital because of chest discomfort and dyspnea. At the time of admission, 16 months after the start of hormone therapy, the prostate-specific antigen level was 454.08 ng/ml. Chest radiography revealed cardiomegaly, and ultrasonography demonstrated significant pericardial effusion. Pericardiocentesis yielded a hemorrhagic exudate, and a routine cytological study revealed malignant cells. It was difficult to determine whether these cells had originated from the prostate cancer or the cholangiocellular carcinoma. However, immunohistochemical analysis of a cell-block section of the pericardial effusion allowed a diagnosis of pericardial metastasis from the prostate cancer. After drainage and intrapericardial injection of cisplatin, the amount of effusion was decreased. After removal of the pericardial drain, the patient was discharged, but the pericardial effusion was found to have accumulated again 1 month later.
引用
收藏
页码:101 / 103
页数:2
相关论文
共 50 条
  • [21] RADIOTHERAPY FOR REGIONALLY LOCALIZED HORMONE-REFRACTORY PROSTATE-CANCER
    LANKFORD, SP
    POLLACK, A
    ZAGARS, GK
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (04): : 907 - 912
  • [22] Present status and perspectives in the treatment of hormone-refractory prostate cancer
    Silvestris, N
    Leone, B
    Numico, G
    Lorusso, V
    De Lena, M
    ONCOLOGY, 2005, 69 (04) : 273 - 282
  • [23] A phase II study of temozolomide in hormone-refractory prostate cancer
    van Brussel, JP
    Busstra, MB
    Lang, MS
    Catsburg, T
    Schröder, FH
    Mickisch, GH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) : 509 - 512
  • [24] A phase II trial of irinotecan in hormone-refractory prostate cancer
    Reese, DM
    Tchekmedyian, S
    Chapman, Y
    Prager, D
    Rosen, PJ
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 353 - 359
  • [25] Pilot study of rapamycin in patients with hormone-refractory prostate cancer
    Amato, Robert J.
    Jac, Jaroslaw
    Mohammad, Taqi
    Saxena, Somya
    CLINICAL GENITOURINARY CANCER, 2008, 6 (02) : 97 - 102
  • [26] A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer
    Ferrero, JM
    Foa, C
    Thezenas, S
    Ronchin, P
    Peyrade, F
    Valenza, B
    Lesbats, G
    Garnier, G
    Boublil, JL
    Tchiknavorian, X
    Chevallier, D
    Amiel, J
    ONCOLOGY, 2004, 66 (04) : 281 - 287
  • [27] New standards in the chemotherapy of metastatic hormone-refractory prostate cancer
    Sava, T
    Basso, U
    Porcaro, A
    Cetto, GL
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 53 - 62
  • [28] Treatment of hormone-refractory prostate carcinoma
    Fournier, G
    EUROPEAN UROLOGY, 1996, 30 : 32 - 37
  • [29] Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy
    Berry, W
    Eisenberger, M
    ONCOLOGIST, 2005, 10 : 30 - 39
  • [30] A phase II trial of irinotecan in hormone-refractory prostate cancer
    David M. Reese
    Simon Tchekmedyian
    Yvonne Chapman
    Diane Prager
    Peter J. Rosen
    Investigational New Drugs, 1998, 16 : 353 - 359